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HIV infection has reached epidemic levels, especially in sub-
Saharan Africa. In South Africa (SA) the prevalence of HIV 
infection is approximately 10%.[1,2] Patients with HIV infection 
are living longer as a result of the availability and access to 
antiretroviral drugs (ARVs) and more chronic complications of 
HIV are therefore being seen. Diabetes mellitus (DM) is one such 
complication.[3] Both ARVs and the severity of HIV infection 
predispose patients to the development of DM.[3-5] HIV-infected 
patients are twice as likely to develop type 2 DM compared with 
HIV-uninfected individuals.[6] Both DM and HIV infection and/or 
ARV use can cause distal sensory peripheral neuropathy (DSP).[7,8] 
The combination of DM and HIV infection represents a collision 
of two chronic conditions.
SA has the third-highest incidence of tuberculosis (TB) worldwide. 
Approximately 1% of the population develops active TB annually.[9] 
Globally DM accounts for 15% of the aetiology of TB. DM increases 
the risk of developing TB three-fold.[6] Diabetic patients who contract 
TB generally have poorer outcomes in respect of higher relapse rates 
and increased risk of death from TB, compared with patients who have 
TB alone.[10] The TB epidemic is fuelled by the increased prevalence 
of HIV infection in SA.[11] The  risk of developing TB increases from 
5 - 10% in a lifetime in HIV-uninfected patients to 5 - 10% per year in 
HIV-infected patients.[12]  The SA National Strategic Plan (NSP) aims 
to decrease the incidence and mortality of TB by half by 2016 and to 
completely eradicate  new TB infections and deaths by 2032.[13] Both 
DM and HIV infection increase the risk of developing TB. Optimal 
control of DM and HIV is essential if we are to achieve the NSP goals 
and limit the spread of TB, thereby decreasing the enormous burden 
that TB places on the economies of developing countries. 
The objective of this study was two-fold:
1.  To establish differences in the following parameters between the 
HIV-infected and uninfected diabetic patients:
• Glycaemic control
• Sitting blood pressure (BP)
• Mean total cholesterol and triglyceride levels
• Nephropathy
• Neuropathy
• Retinopathy
• Body mass index (BMI), waist circumference, glomerular 
filtration rate (GFR), vitamin B12 levels
• Pharmacological management. 
2.  To divide the HIV-infected diabetic cohort into those with and 
without optimal glycaemic control and then to compare the 
following characteristics between the 2 groups:
• Glycaemic control
• Duration of DM
• Sitting BP
• BMI
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Background. The combination of HIV infection and diabetes mellitus (DM) represents a collision of two chronic conditions. Both HIV 
and DM increase the risk of developing tuberculosis (TB). Health resources in developing countries are already under strain as a result of 
the TB epidemic and poor diabetic control would further worsen this epidemic. Optimal diabetic control provides one avenue of curbing 
the TB epidemic in developing countries.
Objectives. To establish if there is a difference in blood pressure, lipid and glycaemic control and complications between HIV-infected and 
uninfected diabetic patients; and to compare characteristics among HIV-infected diabetic patients between those with optimal and sub-
optimal glycaemic control.
Methods. This was a retrospective chart review of all patients who visited the Edendale Hospital diabetic clinic, Pietermaritzburg, from 
1 October 2012 to 30 September 2013. 
Results. There were statistically significant differences noted in the following parameters between HIV-infected and uninfected diabetic 
patients: (i) mean HbA1c% (11.08% v. 10.14%, respectively); (ii) nephropathy defined by proteinuria (25.66% v. 15.43%); (iii) neuropathy 
(48.68% v. 42.10%); and (iv) Kidney Disease Outcomes Quality Initiative (KDOQI) stage ≥2 chronic kidney disease (30.87% v. 41.67%). 
There were no significant differences noted in the percentage of patients achieving the following target parameters between the two 
cohorts: (i) blood pressure (42.11% v. 35.62%); (ii) total cholesterol (36.84% v. 34.67%); and (iii) triglycerides (42.76% v. 40.19%). Within 
the HIV-infected diabetic cohort 85.23% displayed suboptimal glycaemic control. A significant percentage of HIV-infected diabetic patients 
on antiretroviral (ARV) therapy (89.36%) had suboptimal glycaemic control. HIV-infected female diabetic patients showed a significant 
increased waist circumference when compared with their HIV-uninfected counterparts. 
Conclusion. HIV-infected diabetic patients had significantly poorer blood sugar control and a higher incidence of neuropathy and 
nephropathy (when defined by overt proteinuria). There was a non-significant difference noted between the HIV-infected and uninfected 
diabetic patients with regard to blood pressure and lipid control. The majority of HIV-infected patients on ARVs failed to achieve target 
glycaemic control. Obesity remains a global challenge, as noted in both the HIV-infected and uninfected diabetic patients. 
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• Mean waist circumference
• Number of patients on ARVs
• Mean CD4 count
• Mean total cholesterol and triglyceride levels
• Mean GFR.
Our hypothesis was that HIV-infected diabetic patients had 
poorer control of the above clinical and biochemical variables 
and had a higher prevalence of diabetic complications when 
compared with their HIV-uninfected counterparts. The second 
hypothesis was that the majority of HIV-infected patients who had 
suboptimal control also had poor blood pressure and lipid control 
and were on ARVs.
Methods
This was a retrospective study assessing all patients seen at the 
Edendale Hospital diabetic clinic during the period 1 October 
2012 to 30 September 2013. Edendale Hospital is a regional level 
hospital situated in Pietermaritzburg, the capital of KwaZulu-
Natal. This clinic caters to both types 1 and 2 diabetic patients 
aged 13 years and older. In September 2012, a diabetic data 
sheet (Appendix 1) was introduced into the clinic. As part of the 
comprehensive assessment of these diabetic patients, a history 
of retroviral status, cluster of differentiation (CD4) count and 
ARV drugs were collected. The purpose of the data sheet was 
to ensure that there was standardisation in the approach to all 
diabetic patients seen at the clinic. All data were captured into a 
computerised program specifically designed for monitoring and 
research within the clinic. The program is designed to generate 
necessary statistics and graphs. Data of all patients seen during the 
study period were analysed and there were no exclusion criteria 
used for this study.
The Bio-Rad D-10 machine (Bio-Rad, USA) was used for 
analysing the HbA1c values at the laboratory. Both the laboratory 
and the machine are NGSP (National Glycohemoglobin 
Standardization Program) accredited to maintain standardisation 
of HbA1c results. The Adam BMI scale was used to measure 
height, weight and BMI readings (Model MDW-300L). GFR was 
calculated using the Modified Diet in Renal Disease (MDRD) 
formula: GFR=186 × (creatinine (micromol/L)/88.4)-1.154 × 
(age)- 0.203 × (0.742 if female) × (1.210 if black). According to the 
Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines 
there are five stages of chronic kidney disease (CKD) based on 
calculation of GFR.[14]
Postural hypotension was identified when there was a drop in 
systolic BP by 20 mmHg or more and/or a drop in diastolic BP 
by 10 mmHg or more, and autonomic neuropathy was present if 
there was orthostatic hypotension and/or resting tachycardia (heart 
rate ≥100 beats per minute (bpm)). The fundoscopy findings were 
those documented by the Edendale Hospital ophthalmology clinic. 
Urine dipstick proteinuria using Makromed test strips was used as a 
surrogate marker for nephropathy. No microalbumin dipsticks were 
available for testing at the clinic.
The presence on history taking of numbness or pain, together 
with distal sensory loss and/or absent ankle reflexes on clinical 
examination, was used as a marker for DSP. [7]
South African Endocrine and Metabolic Society (SEMDSA) 
guidelines from 2012 were used to define the following goals:[15]
• HbA1c ≤7%
• Blood pressure ≤140/80 mmHg
• Total cholesterol level <4.5 mmol/L
• Triglyceride level <1.7 mmol/L.
Results
Epidemiology
There were 653 first-patient visits during the study period. More 
type 2 diabetic patients were seen (83.46%). One hundred and forty-
nine patients (22.82%) self-reported being HIV-infected. Among the 
HIV-infected diabetic patients, 67.76% were female and the majority 
had type 2 diabetes (82.24%). One hundred and sixteen HIV-infected 
diabetic patients (77.85%) had had diabetes for a period of ≤10 
years. The majority of HIV-uninfected diabetic patients (64.82% for 
type 1 DM and 68.07% for type 2 DM patients) had also had DM 
for ≤10 years. Just over half of the HIV-infected diabetic patients 
(54.36%) seen at the clinic were between 41 and 60 years of age. This 
differed from the HIV-uninfected diabetic patients who were older 
patients aged 51 - 70 years (50.36%).
Glycaemic control
The mean HbA1c achieved in the HIV-infected diabetic cohort v. 
the HIV-uninfected diabetic cohort was 11.08% v. 10.14% (p=0.044), 
respectively (Wilcoxon rank-sum test).
The risk of being HIV-infected for patients who had optimal 
HbA1c control was 1.34 times that of patients who didn’t have 
optimal HBA1c control (odds ratio (OR) 1.34; 95% confidence 
interval (CI) 0.94 - 1.92). The odds of having HIV infection for 
patients with optimal HBA1c control was 1.50 times the odds for 
patients who did not have optimal HBA1c control (OR 1.50; 95% CI 
0.89 - 2.53).
Blood pressure control
The mean BP obtained in the HIV-infected diabetic cohort was 
146/90 mmHg (sitting) and 145/92 mmHg (standing). Target BP 
control in HIV-infected diabetic patients v. HIV-uninfected diabetic 
patients was achieved in 42.11% v. 35.62% (p=0.71), respectively 
(Fisher’s exact test). The risk of being HIV-infected for patients who 
had optimal BP control was 1.06 times that of patients who didn’t 
have optimal BP control (OR 1.06; 95% CI 0.81 - 1.39). The odds 
of having HIV infection for patients with optimal BP control was 
1.08 times greater for patients who did not have optimal BP control 
(OR 1.08; 95% CI 0.75 - 1.56).
Lipid control
Target cholesterol level was achieved in 63.16% and target triglyceride 
levels were achieved in 57.24% of HIV-infected diabetic patients. 
The differences between HIV status and elevated cholesterol levels 
was not statistically significant (p=0.637, Fisher’s exact test). The 
risk of being HIV positive for patients who had elevated cholesterol 
levels was 0.92 times that of patients who did not have elevated 
cholesterol levels (OR 0.92; 95% CI 0.69 - 1.22). The odds of having 
HIV infection for patients with elevated cholesterol levels was 0.90 
times the odds for patients who did not have elevated cholesterol 
levels (OR 0.90; 95% CI 0.62 - 1.30). The differences between HIV 
status and elevated triglyceride levels was not statistically significant 
(p=0.582, Fisher’s exact test). The risk of being HIV positive for 
patients who had elevated triglyceride levels was 0.92 times that of 
patients who didn’t have elevated cholesterol levels (OR 0.92; 95% CI 
0.70 - 1.21). The odds of having HIV infection for patients with 
elevated triglyceride levels  was 0.90 times the odds for patients who 
did not have elevated cholesterol levels (OR 0.90; 95% CI 0.62 - 1.29). 
Table 1 summarises the comparison of those achieving lipid targets.
Diabetes complications
Table 2 illustrates that HIV-infected diabetic patients had significant 
higher prevalence of both nephropathy (when defined by overt 
RESEARCH
380       April 2016, Vol. 106, No. 4
proteinuria) and neuropathy when compared 
with their HIV-uninfected counterparts. 
However, the prevalence of CKD KDOQI 
stage 2 or greater was significantly higher 
in the HIV-uninfected cohort of diabetic 
patients (Tables 2 and 3). 
The mean GFR in our HIV-infected v. our 
HIV-uninfected diabetic patients was 124.89 
mL/min/1.73 m2 v. 113.48 mL/min/1.73 m2 
(p=0.048), respectively (Wilcoxon rank-sum 
test). 
Waist circumference/BMI
More than half (55.91%) of the HIV-infected 
diabetic cohort had a BMI ≥30 kg/m2. The mean 
waist circumference was lower in HIV-infected 
v. HIV-uninfected diabetic males (97.41 cm 
v. 99.69 cm (p=1.61), respectively, Fisher’s 
exact test)). There was a similar trend noted 
in HIV-infected v. HIV-uninfected diabetic 
females (106.65 cm v. 107.54 cm (p=0.55), 
respectively, Fisher’s exact test). HIV-infected 
diabetic female patients with increased waist 
circumferences had poorer glycaemic control 
when compared with their counterparts with 
normal waist circumferences.
Vitamin B12 (cyanocobalamin) 
deficiency
Both HIV-infected and HIV-unifected 
diabetic patients had a high incidence of 
vitamin B12 deficiency (42.76% v. 44.57%, 
respectively). The difference between HIV 
status and vitamin B12 deficiency was not 
significant (p=0.145, Fisher’s exact test).
ARVs and CD4 counts
In this cohort of diabetic HIV-infected 
patients, 51.68% had a documented CD4 
count, and the mean CD4 count was 
491.45 (standard deviation (SD) 271.69) 
cells/ mm3. Table 4 demonstrates that there 
was no significant difference noted between 
glycaemic control (HbA1c percentage) 
observed between patients on ARVs v. those 
that were ARV naive (10.18 v. 10.59, p=0.447, 
respectively) (Mann-Whitney test).
Pharmacological management and 
glycaemic control comparisons 
made between the HIV-infected and 
HIV-uninfected diabetic patients
HIV-uninfected patients on insulin 
monotherapy and those on combination of 
metformin and oral antidiabetic medicines 
(OADs) had significantly better glycaemic 
control than their HIV-infected counterparts. 
There was no statistical difference between 
the mean HbA1c percentage obtained in the 
HIV-infected cohort of diabetic patients who 
were on insulin monotherapy v. those who 
were on a combination of insulin and OADs 
(10.85% v. 11.76%, p=1.00, respectively) 
(Table 5).
Table 6 shows observations noted when 
the HIV-infected diabetic patients were 
grouped into those with v. those without 
optimal glycaemic control. 
Discussion
SA is burdened by the HIV and TB epi-
demics. In addition to this, the burden of 
communi cable diseases such as DM, together 
with its long-term complications, weigh 
heavily on the economy of the country. Both 
HIV and DM increase the risk of developing 
TB, thereby worsening the burden that 
communicable diseases have on the country 
as well. Efforts need to be directed towards 
analysing the control that we are currently 
achieving in these HIV-infected diabetic 
patients. This study’s objectives were to 
describe the control achieved in these HIV-
infected diabetic patients when compared 
with their HIV-uninfected counterparts. 
Glycaemic control achieved in the 
HIV-infected and HIV-uninfected 
diabetic patients
HIV-infected diabetic patients had signifi-
cantly poorer control of their blood glucose 
Table 1. Comparison between HIV-infected and HIV-uninfected diabetic patients in 
respect of achieving target lipid control
HIV-infected, n (%) HIV-uninfected, n (%) p-value*
Triglycerides >1.7 mmol/L 65 (43.62) 211 (41.86) 0.582
Total cholesterol >4.5 mmol/L 56 (37.58) 182 (36.11) 0.637
*Fisher’s exact test.
Table 2. Comparisons in the prevalence of microvascular complications between HIV-
infected and -uninfected diabetic patients
Microvascular complications HIV-infected, n (%) HIV-uninfected, n (%) p-value*
All forms of retinopathy 13 (8.72) 29 (5.75) 0.349
Nephropathy defined by
Proteinuria 39 (26.17) 81 (16.07) 0.035
CKD KDOQI stage 2 or greater 46 (30.87) 210 (41.67) 0.000† 
Resting tachycardia 38 (25.50) 95 (18.85) 0.262
Postural hypotension 47 (31.54) 160 (31.75) 0.437
Autonomic neuropathy 11 (7.38) 48 (9.52) 0.273
Neuropathy 74 (49.66) 221 (43.85) 0.035
*Fisher’s exact test.
† χ2 test.
Table 3. Prevalence of CKD and associated glycaemic control among HIV-infected and 
HIV-uninfected diabetic patients
CKD 
stage
GFR (mL/
min/1.73 m2)
HIV-infected HIV-uninfected
p-value 
HbA1c%*n (%)
Mean CD4 
count 
(cells/mm3)
Mean 
HbA1c% n (%)
Mean 
HbA1c%
1 ≥90 103 (69.13) 298.56 11.23 294 (58.33) 10.78 0.113
2 60 - 89 22 (14.77) 157.55 11.05 111 (22.02) 10.45 0.121
3 30 - 59 16 (10.74) 64.44 12.61 72 (14.29) 9.63 0.867
4 15 - 29 6 (4.03) 431 9.68 18 (3.57) 11.78 0.224
5 <15 2 (1.34) 387.50 12.30 9 (1.79) 10.07 1.000
*Fisher’s exact test.
Table 4. Comparison of glycaemic 
control achieved between patients on 
ARVs v. ARV-naive patients 
HIV-infected 
patients n (%)
Mean 
HbA1c%
On ARVs 47 (31.54) 10.18
ARV-naive 102 (68.46) 10.59
Total 149
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compared with their HIV-uninfected counter-
parts (mean HbA1c 11.08% v. 10.14%). Kim et 
al.[16] showed that the HbA1c values obtained 
in HIV-infected patients are lower than the 
actual value for a variety of reasons including 
higher mean corpuscular volume (MCV) and 
haemolysis. Therefore, our HbA1c of 11.08% 
is probably an underestimation of the actual 
value. This emphasises that our HIV-infected 
patients are not achieving optimal control. 
Only ~1 in 7 (14.76%) of our diabetic HIV-
infected patients actually achieved target 
HbA1c levels. This is in stark contrast to other 
studies carried out abroad which show a 30 - 
67% target HbA1c attainment in their HIV-
infected diabetic patients.[17,18]
The majority of the HIV-infected diabetic 
patients (85.23%) displayed suboptimal 
glycaemic control. A significant percentage 
of HIV-infected diabetic patients on ARVs 
(89.36%) failed to achieve optimal gly cae-
mic control. HIV-infected female diabetic 
patients showed a significant difference in 
waist circumference when compared with 
their HIV-uninfected counterparts. 
BP control
The United Kingdom Prospective Diabetes 
Study (UKPDS) established that intensive BP 
control in the management of DM forms an 
integral part of preventing complications.[8] 
Fewer than half (42.11%) of our HIV-infected 
patients achieved target BP. This figure is much 
lower than that reported by Adeyemi et al.[17] 
(56%) in 2009, but similar to what Satlin 
et al.[18] found in their study published in 
2011. The results from our study indicated no 
significant difference in BP control between 
the HIV-infected and HIV-uninfected patients.
Lipid control 
A significant proportion of all diabetic 
patients (both HIV-infected and uninfected) 
seen at our clinic had hyperlipidaemia. 
Previous studies have shown an increased 
risk for metabolic syndrome in HIV-infected 
diabetic patients.[5] The majority of HIV-
infected diabetic patients managed to achieve 
optimal lipid control. However, there was 
no significant difference in lipid control 
between the two cohorts.
Renal complications
HIV-infected diabetic patients showed a 
higher prevalence of nephropathy when 
nephropathy was defined using overt 
proteinuria diagnosed on urine dipstick 
measurement. Both HIV and DM increase 
the risk of developing proteinuria, chronic 
renal disease and renal failure.[19] Our 
cohort demonstrated this phenomenon, with 
25.66% having overt proteinuria detected on 
routine urine dipstick testing. Renal disease 
in DM is an ever-present threat, more so 
for diabetic patients with concomitant HIV 
infection. Our study further demonstrated 
that the incidence of CKD based on GFR 
measurements was significantly higher in 
the HIV-unifected diabetic patient. The 
mean GFR was higher in HIV-infected 
diabetic patients. This is probably explained 
by the younger age range of the HIV-infected 
v. uninfected diabetic patients noted in our 
study (41 - 60 v. 51 - 70 years, respectively).  
Neuropathy
The prevalence of neuropathy was signifi-
cantly higher in the HIV-infected v. the 
un in fec ted diabetic patients. As mentioned 
earlier DM, HIV infection and ARVs all 
increase the patient’s risk of developing 
neuropathy.[7,8]
Management issues surrounding 
HIV-infected v. HIV-uninfected 
diabetic patients
An average waist circumference of ≥86  cm 
for males and ≥92 cm for females was 
used as an indicator of central obesity.[20]
Although the HIV-infected cohort had a 
lower mean waist circumference than their 
HIV-uninfected counterparts, they still met 
the above criteria for central obesity in both 
males and females. This increased central 
Table 5. Pharmacological treatment groups and their associated glycaemic control
HIV-infected HIV-uninfected 
p-value for 
HbA1c%*n (%)
Mean 
HbA1c% n (%)
Mean 
HbA1c%
Metformin 5 (3.36) 9.72 19 (3.77) 9.21 0.458
Other OADs† 1 (0.67) 15.60 5 (0.99) 9.16 0.457
Insulin monotherapy 54 (36.24) 10.85 132 (26.19) 10.53 0.005
Combination of insulin and 
OADs 66 (44.30) 11.76 252 (50.00) 11.05 0.507
Combination of metformin 
and other OADs 23 (15.44) 11.20 96 (19.05) 9.68 0.003
Total 149 504
*Fisher’s exact test.
† Includes glibenclamide and/or glicazide.
Table 6. HIV-infected diabetic patients stratified according to glycaemic control
Optimal control 
HbA1c ≤7%
Suboptimal control 
HbA1c >7% p-value*
Males, n (%) 9 (6.04) 38 (25.50) 0.000*
Females, n (%) 13 (8.72) 89 (59.73) 0.000*
HbAc1 (%), mean (SD) 6.17 (1.39) 11.33 (2.87) 0.000
Duration of DM (years), mean (SD) 4.29 (4.65) 7.25 (6.16) 0.100
Sitting BP (mmHg), mean 140/86 134/83
BMI (kg/m2), mean (SD)
Males 27.56 (3.93) 28.27 (5.97) 0.760
Females 28.31 (10.00) 33.74 (13.69) 0.130
Waist circumference (cm), mean (SD)
Males 93.25 (12.89) 94.97 (26.35) 0.800
Females 69.80 (51.55) 99.05 (24.66) 0.030
Patients on ARVs, n (%) 5 (3.36) 42 (28.19) 0.000† 
CD4 count (cells/mm3), mean (SD) 534.86 (326.92) 481.49 (259.51) 0.510
Total cholesterol level (mmol/L), mean 4.58 6.85 0.760
Triglyceride level (mmol/L), mean 2.14 2.16 1.000
GFR (mL/min/1.73m2), mean (SD) 99.55 (49.05) 127.75 (46.46) 0.050
* Fisher’s exact test.
† χ2 test.
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obesity increases their risk of developing DM. Our HIV-infected 
cohort demonstrated a high incidence of obesity (55.91%); hence the 
need for reinforcement of lifestyle modification remains one of the 
cornerstones of modalities of treatment, irrespective of whether a 
patient is HIV-infected or not.
Metformin has been shown to improve insulin resistance in 
diabetic patients with HIV infection; however metformin use in HIV-
infected patients has been associated with more cases of diarrhoea, 
decreases in subcutaneous fat and lactic acidosis.[3] Sulphonylureas 
are usually safe but their action may make them ineffective when 
there is severe insulin resistance. The best drug to treat DM in HIV-
infected patients would be insulin as it has a positive growth effect 
and little or no drug interactions with ARVs and it can be used in 
patients with hepatic and renal dysfunction.[21,22] Just over a third of 
our patients (36.24%) were on insulin monotherapy and a further 
44.30% were on a combination of insulin and OADs. Our results 
show that there was no significant difference in glycaemic control 
between those taking insulin monotherapy and those taking a 
combination of insulin and OADs within the HIV-infected cohort of 
patients. HIV-unifected patients on insulin monotherapy and those 
on metformin and other OADs had significantly better glycaemic 
control when compared with their HIV-infected counterparts.
Increased BMI, waist circumferences and low CD4 counts are 
associated with increased risk of development of DM in HIV-infected 
patients.[5,6] Our HIV-infected cohort had a relatively low mean (SD) 
CD4 of 228.94 (307.60) cells/mm3, which increased the possibility of 
developing DM.
Vitamin B12 deficiency
The study revealed that a significant percentage of our diabetic 
patients (both HIV-infected and HIV-uninfected) had vitamin B12 
deficiency. However, there was no significant difference observed 
between the two groups of diabetic patients. Vitamin B12 deficiency in 
these patients warrants  further investigation as the aetiology could be 
multifactorial,  ranging from poor dietary intake and malabsorption 
syndromes associated with HIV infection to metformin-associated 
vitamin B12 deficiency.
Study limitations
HIV status of the patients required self-reporting and was probably 
underreported by patients owing to issues around social stigma.
Dates of diagnosis of HIV and initiation of ARVs were not 
routinely collected. This would have helped in establishing whether 
HIV and/or the ARVs prescribed could have potentiated the onset of 
DM in these patients.
The subgroup of nephropathy in HIV-infected diabetic patients 
involved only a small number of patients. 
Conclusion
HIV-infected diabetic patients had significantly poorer glycaemic 
control with higher prevalences of complications (viz. neuropathy 
and nephropathy when defined by proteinuria) than their HIV-
uninfected counterparts. Although no significant differences were 
noted between HIV-infected and HIV-unifected diabetic patients 
with regard to optimal BP achieved, a significant proportion 
(57.89%) of the HIV-infected patients failed to achieve optimal BP 
control. The majority of HIV-infected diabetic patients managed 
to achieve optimal lipid control. Within the group of HIV-infected 
patients who had suboptimal glycaemic control it was found that 
the majority were on ARVs and had suboptimal lipid control.
This study provides a baseline illustrating that we are achieving 
suboptimal glycaemic and BP control in our diabetic patients, 
both HIV-infected and uninfected. This spells disaster, as the 
combination of HIV and poor glycaemic control will increase the 
risk of these patients developing TB and will further worsen the 
current burden of communicable diseases on developing countries 
like SA. It is now our duty to work from this baseline to assist 
our patients in gaining better control of their diabetes and thus 
improving their quality of life.
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